168 related articles for article (PubMed ID: 34749311)
21. Are we doing enough to prevent poor-quality antimalarial medicines in the developing world?
Walker EJ; Peterson GM; Grech J; Paragalli E; Thomas J
BMC Public Health; 2018 May; 18(1):630. PubMed ID: 29764407
[TBL] [Abstract][Full Text] [Related]
22. Artemisinin resistance--modelling the potential human and economic costs.
Lubell Y; Dondorp A; Guérin PJ; Drake T; Meek S; Ashley E; Day NP; White NJ; White LJ
Malar J; 2014 Nov; 13():452. PubMed ID: 25418416
[TBL] [Abstract][Full Text] [Related]
23. Economic cost of substandard and falsified human medicines and cosmetics with banned ingredients in Tanzania from 2005 to 2015: a retrospective review of data from the regulatory authority.
Mori AT; Meena E; Kaale EA
BMJ Open; 2018 Jun; 8(6):e021825. PubMed ID: 29950474
[TBL] [Abstract][Full Text] [Related]
24. Estimated under-five deaths associated with poor-quality antimalarials in sub-Saharan Africa.
Renschler JP; Walters KM; Newton PN; Laxminarayan R
Am J Trop Med Hyg; 2015 Jun; 92(6 Suppl):119-126. PubMed ID: 25897068
[TBL] [Abstract][Full Text] [Related]
25. Subsidising artemisinin-based combination therapy in the private retail sector.
Opiyo N; Yamey G; Garner P
Cochrane Database Syst Rev; 2016 Mar; 3(3):CD009926. PubMed ID: 26954551
[TBL] [Abstract][Full Text] [Related]
26. Cost-effectiveness of pre-referral antimalarial, antibacterial, and combined rectal formulations for severe febrile illness.
Buchanan J; Mihaylova B; Gray A; White N
PLoS One; 2010 Dec; 5(12):e14446. PubMed ID: 21206901
[TBL] [Abstract][Full Text] [Related]
27. Prices and mark-ups on antimalarials: evidence from nationally representative studies in six malaria-endemic countries.
Palafox B; Patouillard E; Tougher S; Goodman C; Hanson K; Kleinschmidt I; Torres Rueda S; Kiefer S; O'Connell K; Zinsou C; Phok S; Akulayi L; Arogundade E; Buyungo P; Mpasela F; Poyer S; Chavasse D
Health Policy Plan; 2016 Mar; 31(2):148-60. PubMed ID: 25944705
[TBL] [Abstract][Full Text] [Related]
28. Detection of Poor Quality Artemisinin-based Combination Therapy (ACT) Medicines Marketed in Benin Using Simple and Advanced Analytical Techniques.
Yemoa A; Habyalimana V; Mbinze JK; Crickboom V; Muhigirwa B; Ngoya A; Sacre PY; Gbaguidi F; Quetin-Leclercq J; Hubert P; Marini RD
Curr Drug Saf; 2017; 12(3):178-186. PubMed ID: 28625144
[TBL] [Abstract][Full Text] [Related]
29. The malaria testing and treatment landscape in Benin.
; Zinsou C; Cherifath AB
Malar J; 2017 Apr; 16(1):174. PubMed ID: 28446236
[TBL] [Abstract][Full Text] [Related]
30. Understanding private sector antimalarial distribution chains: a cross-sectional mixed methods study in six malaria-endemic countries.
Palafox B; Patouillard E; Tougher S; Goodman C; Hanson K; Kleinschmidt I; Rueda ST; Kiefer S; O'Connell KA; Zinsou C; Phok S; Akulayi L; Arogundade E; Buyungo P; Mpasela F; Chavasse D
PLoS One; 2014; 9(4):e93763. PubMed ID: 24699934
[TBL] [Abstract][Full Text] [Related]
31. Progress toward elimination of malaria in Nigeria: uptake of artemisinin-based combination therapies for the treatment of malaria in households in Benin City.
Akoria OA; Arhuidese IJ
Ann Afr Med; 2014; 13(3):104-13. PubMed ID: 24923369
[TBL] [Abstract][Full Text] [Related]
32. Surveillance for falsified and substandard medicines in Africa and Asia by local organizations using the low-cost GPHF Minilab.
Petersen A; Held N; Heide L;
PLoS One; 2017; 12(9):e0184165. PubMed ID: 28877208
[TBL] [Abstract][Full Text] [Related]
33. Implementation of field detection devices for antimalarial quality screening in Lao PDR-A cost-effectiveness analysis.
Luangasanatip N; Khonputsa P; Caillet C; Vickers S; Zambrzycki S; Fernández FM; Newton PN; Lubell Y
PLoS Negl Trop Dis; 2021 Sep; 15(9):e0009539. PubMed ID: 34591842
[TBL] [Abstract][Full Text] [Related]
34. Quality of artemisinin-based combination formulations for malaria treatment: prevalence and risk factors for poor quality medicines in public facilities and private sector drug outlets in Enugu, Nigeria.
Kaur H; Allan EL; Mamadu I; Hall Z; Ibe O; El Sherbiny M; van Wyk A; Yeung S; Swamidoss I; Green MD; Dwivedi P; Culzoni MJ; Clarke S; Schellenberg D; Fernández FM; Onwujekwe O
PLoS One; 2015; 10(5):e0125577. PubMed ID: 26018221
[TBL] [Abstract][Full Text] [Related]
35. Quality Testing of Artemisinin-Based Antimalarial Drugs in Myanmar.
Guo S; Kyaw MP; He L; Min M; Ning X; Zhang W; Wang B; Cui L
Am J Trop Med Hyg; 2017 Oct; 97(4):1198-1203. PubMed ID: 28820713
[TBL] [Abstract][Full Text] [Related]
36. Home- or community-based programmes for treating malaria.
Okwundu CI; Nagpal S; Musekiwa A; Sinclair D
Cochrane Database Syst Rev; 2013 May; 2013(5):CD009527. PubMed ID: 23728693
[TBL] [Abstract][Full Text] [Related]
37. Interventions to improve the use of antimalarials in south-east Asia: an overview.
Gomes M; Wayling S; Pang L
Bull World Health Organ; 1998; 76 Suppl 1(Suppl 1):9-19. PubMed ID: 9763718
[TBL] [Abstract][Full Text] [Related]
38. Indirect effects of the COVID-19 pandemic on malaria intervention coverage, morbidity, and mortality in Africa: a geospatial modelling analysis.
Weiss DJ; Bertozzi-Villa A; Rumisha SF; Amratia P; Arambepola R; Battle KE; Cameron E; Chestnutt E; Gibson HS; Harris J; Keddie S; Millar JJ; Rozier J; Symons TL; Vargas-Ruiz C; Hay SI; Smith DL; Alonso PL; Noor AM; Bhatt S; Gething PW
Lancet Infect Dis; 2021 Jan; 21(1):59-69. PubMed ID: 32971006
[TBL] [Abstract][Full Text] [Related]
39. A New Handheld Device for the Detection of Falsified Medicines: Demonstration on Falsified Artemisinin-Based Therapies from the Field.
Wilson BK; Kaur H; Allan EL; Lozama A; Bell D
Am J Trop Med Hyg; 2017 May; 96(5):1117-1123. PubMed ID: 28219992
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
